What is the most recent earnings date for URGN stock?
UROGEN PHARMA LTD (URGN) last reported earnings on 3/2/2026.
UROGEN PHARMA LTD (URGN) Earnings History & Surprises
NASDAQ:URGN • IL0011407140
Current stock price
18.545 USD
-0.18 (-0.99%)
Last:
URGN Earnings overview
Past quarterly earnings results for UROGEN PHARMA LTD (URGN), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.56
- Revenue Estimate
- 45.032M
Last Reported
Most Recent- Release Date
- Mar 2, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$0.54
- EPS Surprise
- -5.36%
- Revenue Surprise
- -7.08%
Beat Rate
Last 8 Quarters 31%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.54 | -0.51 | -5.36% | 32.50% | 37.837M | 40.721M | -7.08% | 54.03% |
| Q3 2025 | -0.69 | -0.71 | 2.31% | -25.45% | 27.482M | 33.755M | -18.58% | 9.04% |
| Q2 2025 | -1.05 | -0.85 | -23.47% | -15.38% | 24.215M | 23.598M | 2.61% | 10.83% |
| Q1 2025 | -0.92 | -0.82 | -12.75% | 5.15% | 20.254M | 23.26M | -12.92% | 7.84% |
| Q4 2024 | -0.80 | -0.73 | -8.93% | -11.11% | 24.565M | 26.147M | -6.05% | 4.40% |
| Q3 2024 | -0.55 | -0.83 | 34.01% | 19.12% | 25.204M | 24.688M | 2.09% | 20.87% |
| Q2 2024 | -0.91 | -0.85 | -7.23% | 11.65% | 21.848M | 24.442M | -10.61% | 3.35% |
| Q1 2024 | -0.97 | -0.88 | -9.81% | 25.38% | 18.781M | 21.809M | -13.88% | 9.24% |
| Q4 2023 | -0.72 | -0.69 | -3.81% | 40.98% | 23.53M | 23.02M | 2.22% | 30.07% |
| Q3 2023 | -0.68 | -0.86 | 21.20% | 39.98% | 20.852M | 20.43M | 2.07% | 29.52% |
| Q2 2023 | -1.03 | -1.16 | 11.11% | 12.71% | 21.139M | 20.523M | 3.00% | 27.34% |
| Q1 2023 | -1.30 | -1.36 | 4.17% | -4.00% | 17.192M | 17.525M | -1.90% | 26.78% |
| Q4 2022 | -1.22 | -1.09 | -11.44% | 3.94% | 18.09M | 18.882M | -4.19% | 11.87% |
| Q3 2022 | -1.13 | -1.18 | 3.97% | 16.07% | 16.1M | 20.549M | -21.65% | 41.85% |
| Q2 2022 | -1.18 | -1.30 | 9.27% | -0.85% | 16.6M | 17.576M | -5.55% | 27.40% |
| Q1 2022 | -1.25 | -1.36 | 8.09% | -6.84% | 13.56M | 15.482M | -12.41% | 81.04% |
| Q4 2021 | -1.27 | -1.20 | -5.97% | 7.97% | 16.17M | 16.822M | -3.88% | 102.89% |
| Q3 2021 | -1.35 | -1.32 | -2.47% | -3.05% | 11.35M | 15.728M | -27.84% | 228.03% |
| Q2 2021 | -1.17 | -1.15 | -1.87% | 18.75% | 13.03M | 11.955M | 8.99% | 3,421.62% |
| Q1 2021 | -1.17 | -1.32 | 11.42% | 34.64% | 7.49M | 9.234M | -18.89% | - |
| Q4 2020 | -1.38 | -1.40 | 1.34% | - | 7.97M | 7.72M | 3.24% | - |
| Q3 2020 | -1.31 | -1.52 | 14.09% | - | 3.46M | 3.405M | 1.62% | - |
| Q2 2020 | -1.44 | -1.61 | 10.77% | - | 370K | 264.517K | 39.88% | - |
| Q1 2020 | -1.79 | -1.65 | -8.62% | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
1
Average EPS beat (4)
-10.71%
Max EPS beat (4)
2.31%
Min EPS beat (4)
-23.47%
Revenue beat statistics
Revenue beat (4)
1
Average Revenue beat (4)
-8.74%
Max Revenue beat (4)
2.61%
Min Revenue beat (4)
-18.58%
Analysis
In the last 4 quarters, URGN has beaten EPS estimates in 1 out of 4 releases
URGN has beaten revenue estimates in 1 out of the last 4 releases
In the last 4 quarters, URGN reported -10.7% below the EPS estimates on average.
In the last 4 quarters, URGN reported -8.7% below the revenue estimates on average.
Related analysis
UROGEN PHARMA LTD / URGN Earnings FAQ
Can you provide information on whether UROGEN PHARMA LTD beat earnings estimates in the last quarter?
UROGEN PHARMA LTD (URGN) missed EPS estimates and missed revenue estimates in the most recent quarter.
Can you provide information on how often UROGEN PHARMA LTD beats earnings estimates?
In the last 4 quarters, UROGEN PHARMA LTD (URGN) has beaten EPS estimates in 1 out of 4 releases.